报告：2020年全球宫颈癌筛查市场将达到220亿美元

宫颈癌（Cervical Cancer）是全球第三大女性恶性肿瘤，是中国女性第二大最常见恶性肿瘤。根据世界卫生组织（WHO）估计，全球每年新增宫颈癌病例超过47万例，而中国占到了28%。若缺乏适当有效的筛查方法及预防措施，到2025年，亚洲宫颈癌发病率将上升40%。

人乳头瘤病毒（HPV）是导致宫颈癌的罪魁祸首，这是一种极为常见的病毒，有高达75%的女性在一生的某一阶段都会感染HPV，大多数女性能够凭借自身免疫力将病毒清除；但如果是长期持续感染HPV，宫颈处于反复感染状况，细胞往往就会发生变异引发癌变。HPV持续感染是宫颈癌及其癌前病变——宫颈上皮内瘤变（CIN）的主要病因，且宫颈病变程度越重，高危HPV感染率越高。

幸运的是，宫颈癌病因明确且发展过程中存在较长的、可逆转的癌前病变期，是唯一一种能够通过医学干预降低发病率和死亡率的恶性肿瘤。这意味着宫颈癌在很大程度上是一种可以预防的疾病。

几十年来，女性一直依靠宫颈细胞学检查（巴氏涂片，pap test）作为检测宫颈癌存在与否的工具。但随着医学技术的发展，近年来已开发出了液基薄层细胞学检测（TCT）及HPV基因检测，用于宫颈癌的筛查。

2020年全球宫颈癌筛查市场将达到220亿美元

近日，美国市场研究机构Markets and Markets发布的最新研究报告显示，全球宫颈癌筛查市场将在2020年达到220亿美元，该市场在2014年价值150亿美元，在预测期（2015-2020）内的年复合增长率（CAGR）为7.0%。

报告指出，中老年女性人口的增长、HPV感染的高发率、宫颈癌发病率的上升、宫颈癌筛查宣传的增加、有利的政府项目及资金支持，是推动全球宫颈癌筛查市场增长的主要因素。根据报告，全球宫颈癌筛查市场可根据检测类型、终端用户、地域进一步划分。

——按检测类型划分，全球宫颈癌筛查市场可细分为巴氏涂片检测（pap test）、HPV检测、联合检测（co-test，细胞学及高危HPV检测），其中HPV/联合检测在预测期内预计将以更高的CAGR增长；这一增长在很大程度上归功于宫颈癌发病率的上升、HPV检测和联合检测（co-test）结果的更高一致性和有效性降低了年度治疗成本、有利于HPV检测的监管条例变化。

——按终端用户划分，全球宫颈癌筛查市场可细分为医院、实验室、独立的医生办公室和诊所。在2014年，实验室占据了最大的市场份额；然而，由于医院患者容量的不断增长，医院细分市场将在预测期内取得更快速的增长。

——按地域划分，全球宫颈癌筛查市场可细分为北美、欧洲、亚太、其他国家（RoW）。其中，北美占有最大的市场份额，其次是欧洲。在未来5年内，这2大主要市场预计将以个位数增长，而亚太地区在预测期内将以更高的速度增长，这得益于该地区巨大的投资机会，这一地区的市场增长将主要围绕在中国、印度、澳大利亚和中东国家。

报告指出，全球宫颈癌筛查及试剂盒市场的主要参与者包括：Hologic公司（美国）、Qiagen N.V（荷兰）、Becton-Dickinson（美国）、罗氏（瑞士）。（生物谷Bioon.com）

英文原文：Cervical Cancer Screening Market worth $22 Billion by 2020

The report “Cervical Cancer Screening Market by Test Type (PAP, HPV), Kit Type (PAP, HPV), End User (Hospitals, Laboratories, Physicians’ Offices & Clinics) - Global Forecast to 2020”, provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the market along with estimates and forecast of revenue.

The cervical cancer screening market is poised to reach $22 billion by 2020 from ~$15 billion in 2014, at an estimated CAGR of 7.0% from 2015 to 2020. Factors such as rising prevalence of cervical cancer and favorable government initiatives and funding to increase disease awareness are driving the global market. However, the availability of HPV vaccines, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market.

The global market is segmented on the basis of test types, end users, and geographies. Based on test type, the cervical cancer screening market is segmented into pap tests and HPV/co tests. Among both, the HPV/co-test is estimated to grow at a higher CAGR during the forecast period. This growth can largely be attributed to the growing incidences of cervical cancer, higher consistency and effectiveness of HPV tests and co-tests that reduce the annual cost of the treatment and changing regulatory guidelines in favor of HPV tests.

On the basis end users, the global market is classified into hospitals, laboratories, and independent physicians’ offices and clinics. The laboratories segment accounted for the largest share in 2014, while the hospitals segment is estimated to grow at a faster rate due to the increasing volume of patients in hospitals.

On the basis of geography, the global market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2014, North America accounted for the largest share of the global market, followed by Europe. Both these markets are estimated to register single-digit growth rates over the next five years. However, Asia-Pacific is expected to register a higher growth rate during the forecast period, owing to huge investment opportunities in this region. Growth of the cervical cancer screening market in the Asia-Pacific region will revolve around China, India, Australia, and countries in the Middle East.

The key players in the cervical cancer screening tests and kits market are Hologic (U.S.), Qiagen N.V. (Netherlands), Becton, Dickinson and Company (U.S.), and Hoffman-La Roche (Switzerland).